ContraFect_LOGO_Web.jpg
ContraFect Announces Multiple Presentations of New Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Address Antimicrobial Resistance at the 32nd Annual ECCMID Meeting
18 avr. 2022 07h30 HE | ContraFect Corporation
YONKERS, N.Y., April 18, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
Graphical Research.jpg
Antimicrobial Coatings Market Size & Share | North America, Europe, & APAC Industry Forecasts 2026: Graphical Research
23 févr. 2022 05h00 HE | Graphical Research
Pune, India, Feb. 23, 2022 (GLOBE NEWSWIRE) -- The global antimicrobial coatings market size is projected to show tremendous growth during the forecast timeframe. The COVID-19 pandemic was...
ContraFect_LOGO_Web.jpg
ContraFect Announces Issuance of Composition of Matter Patent for CF-370 by the United States Patent and Trademark Office
03 mai 2021 07h30 HE | ContraFect Corporation
YONKERS, N.Y., May 03, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect_LOGO_Web.jpg
ContraFect Corporation Announces Proposed Public Offering of Common Stock
17 mars 2021 16h01 HE | ContraFect Corporation
YONKERS, N.Y., March 17, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the...
ContraFect_LOGO_Web.jpg
ContraFect Announces up to $18.9 Million in Funding from CARB-X to Support Acceleration of the CF-370 Program for Treating Pseudomonas aeruginosa Infections towards Clinical Stage Development
20 juil. 2020 07h30 HE | ContraFect Corporation
YONKERS, N.Y., July 20, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
Dan Hassett, PhD, in his laboratory at the University of Cincinnati
Arch Scientist Publishes Data on the Pre-Clinical Efficacy of AB569 in Killing of Drug Resistant Bacteria
21 févr. 2020 08h00 HE | Arch Biopartners
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9328b8b7-9f45-4361-915c-3a569b3716a0 TORONTO, Feb. 21, 2020 (GLOBE NEWSWIRE) --  Arch...
logo.png
Arch Biopartners Announces AB569 Phase I Human Trial Begins Patient Recruitment and Enrollment Stage
13 févr. 2018 08h00 HE | Arch Biopartners
TORONTO, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture:ARCH) (OTCBB:ACHFF) a portfolio based biotechnology company, announced today the investigator...
GMILogo_Vertical-Gradient.png
Antimicrobial Coatings Market worth $7bn by 2024: Global Market Insights, Inc.
10 avr. 2017 07h30 HE | Global Market Insights, Inc
Ocean View, Delaware, April 10, 2017 (GLOBE NEWSWIRE) -- The research report “Antimicrobial Coatings Market Size By Product (Antimicrobial Powder Coatings [Silver], Surface Modifications and...
Achaogen, Inc.
Achaogen Reports First Quarter 2016 Financial Results
05 mai 2016 16h05 HE | Achaogen, Inc.
-- Accelerated Timeline for Reporting Top-Line Results from Phase 3 EPIC Registration Clinical Trial of Plazomicin; Top-Line Data in First Quarter of 2017 and NDA Submission in Second Half of 2017...
DUX Dental Logo
German Study Finds Bacteria on Seventy Percent of Dental Bib Holders
19 mars 2012 13h43 HE | DUX Dental
OXNARD, Calif., March 19, 2012 (GLOBE NEWSWIRE) -- This week, researchers at the University of Witten/Herdecke in North Rhine-Westphalia, Germany released a clinical study indicating that the...